Sotatercept and cardiopulmonary comorbidities
- Robyn Kalda
- Jun 8
- 1 min read
This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery disease, high blood pressure, lung scarring, or COPD.
After six months of treatment, patients generally needed less oxygen, walked farther in six-minute walk tests, and showed improvements in their overall risk scores. Most side effects, such as nosebleeds or increased red blood cell levels, were mild. The results suggest that sotatercept may be both safe and helpful even in more PAH patients with cardiopulmonary comorbidities that excluded them from earlier clinical trials.
Interesting that even patients with comorbidities like COPD or lung scarring still showed meaningful gains in walk distance and oxygen needs. I've been tracking similar real-world PAH data with https://veo3-ai.pro
It’s encouraging to see real-world data on sotatercept for PAH patients with comorbidities like COPD or lung scarring—especially the improvements in six-minute walk distance and oxygen needs. I’ve been tracking similar outcomes with https://myminifactory.pro
Interesting to see real-world data confirming sotatercept's benefits even in PAH patients with comorbidities like COPD or CAD. I've been tracking similar outcomes with https://motion-control-ai.org
Interesting that even with comorbidities like COPD or coronary disease, patients still showed better walk distances and oxygen needs on sotatercept. I've been tracking real-world PAH outcomes with https://hy-3d.net
Interesting to see real-world data backing up the trial results, especially the reduced oxygen needs and improved walk distance in PAH patients with comorbidities like COPD. I've been tracking similar outcomes with https://veovideoai.com